MedTrace Logo

ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer

NCT01779206 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 4936

Last updated 2025-04-08

No results posted yet for this study

Summary

Trial for the optimization of risk assessment and therapy success prediction in patients with early breast cancer by the use of biomarkers in advance to therapy decision-making to personalize therapies.

Conditions

Interventions

DRUG

Epirubicin

DRUG

Cyclophosphamide

DRUG

Docetaxel

DRUG

Paclitaxel

Sponsors & Collaborators

  • West German Study Group

    lead OTHER

Principal Investigators

  • Nadia Harbeck, Prof. Dr. · Breast Center of the University of Munich (LMU) Universitätsfrauenklinik Großhadern, Munich, Germany

  • Ulrike Nitz, Prof. Dr. · Ev. Krankenhaus Bethesda Brustzentrum Niederrhein, Mönchengladbach, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2019-09-30
Completion
2025-01-15

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01779206 on ClinicalTrials.gov